Abstract:Statins are the most prescribed drug for regulating the high cholesterol level in the blood, which can lead to severe complications, such as cardiovascular diseases and other health complications. A wide range of analytical techniques have been employed for the quantification of statins from various origins, including fermentation derived (lovastatin, pravastatin, and compactin), semi-synthetic (simvastatin), and synthetic (atorvastatin, rosuvastatin, and fluvastatin) routes. The presence of more than one structural form and structural analogue generated in the biosynthesis pathway, as well as reaction intermediates and macromolecules in the clinical sample, complicates the quantification of statins. Furthermore, significant concentrations of statins in environmental samples pose serious health and ecology hazards, and estimating statins in those diluted samples is extremely difficult. On the other hand, the: cost, accurate estimation of the desired one from other structural forms, sample complexity, time, limits of detection and quantification, were major criteria distinguishing the usability of each technique. As a result, the current manuscript focuses on analytical techniques such as molecular spectroscopy (normal and derivatives UV-Visible spectrophotometer), chromatography (TLC, HP-TLC, HPLC, GC, swing column, micellar, and supercritical fluid), mass spectroscopy (HPLC-MS/MS and GC-MS/MS), sequential flow injection, capillary electrophoresis, and cyclic voltammetry, as well as their: optimal operating conditions, limits of detection and quantification, advancements, and limitations. Furthermore, various online and offline sample preparations (precipitation, solid phase extraction, liquid-liquid extraction, and micellar extraction) have been highlighted as an essential pretreatment technique to avoid the interference caused by structural analogues and other macromolecules. The greener and more sustainable concepts used in analytical approaches for the quantification statins are also highlighted with current advancements.

Recent Advances in the Synthesis and Analysis of Atorvastatin and Its Intermediates

Progress in Total Synthesis of Atrovastatin

Study on Synthetic Routes of Atorvastatin Calcium of Hypolipidemic Drugs

A Novel and Efficient Route for the Preparation of Atorvastatin

Synthesis of a New Antihyperlipidaemic Agent-Simvastatin

Synthetic studies on statins. Part 1: A short and cyanide-free synthesis of atorvastatin calcium via an enantioselective aldol strategy

Efficient Synthesis of the Nucleus of Atorvastatin Calcium

Asymmetric Synthesis of Atorvastatin Calcium through Intramolecular Oxidative Oxygen-Nucleophilic Bromocyclization

Asymmetric Synthesis of the HMG-CoA Reductase Inhibitor Atorvastatin Calcium: an Organocatalytic Anhydride Desymmetrization and Cyanide-Free Side Chain Elongation Approach.

An Evaluation Of Pitavastatin For The Treatment Of Hypercholesterolemia

Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia.

Summary of Synthesis Methods of Olmesartan Medoxomil and Key Intermediates

An Improved Process for Chiron Synthesis of the Atorvastatin Side Chain

Critical analysis of analytical techniques developed for statins in biological fluids, environmental and fermentation samples

Synthetic studies on statins. Part 3: A facile synthesis of rosuvastatin calcium through catalytic enantioselective allylation strategy

Enhanced Single-Step Bioproduction of the Simvastatin Precursor Monacolin J in an Industrial Strain of Aspergillus Terreus by Employing the Evolved Lovastatin Hydrolase

Progress in clinical pharmacology of atorvastatin coadministrated with acipimox

Efficient Synthesis of Valsartan, A Nonpeptide Angiotensin Ii Receptor Antagonist

Enhancing the biopharmaceutical attributes of atorvastatin calcium using polymeric and lipid-polymer hybrid nanoparticles: An approach for atherosclerosis treatment

Improvement in Synthesis of the Intermediate of Pitavastatin

Method for preparing atorvastatin calcium key intermediate